v3.25.2
Segment Data (Schedule of Segment Reporting Information by Business Segment) (Details)
$ in Millions
3 Months Ended 6 Months Ended
Jun. 27, 2025
USD ($)
Jun. 28, 2024
USD ($)
Jun. 27, 2025
USD ($)
segement
Jun. 28, 2024
USD ($)
Net sales $ 485.1 $ 514.3 $ 905.0 $ 982.1
Operating Income (Loss) 33.0 27.4 48.0 9.7
Restructuring charges, net 0.2 (0.2) 2.2 (10.4)
Separation Costs [1] (2.2) (10.3) (3.6) (17.0)
Interest Expense (32.6) (59.4) (65.4) (118.5)
Interest income 5.9 6.0 11.7 12.8
Other income (expense), net 7.2 (3.5) 1.4 0.2
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 13.0 (29.5) $ (11.0) (95.8)
Number of Reportable Segments | segement     2  
Cost of sales 253.3 319.3 $ 470.3 623.1
Selling, general and administrative expenses 150.6 127.9 298.1 264.8
Research and development expenses 23.6 29.2 44.1 57.1
Depreciation and amortization     44.8 67.2
Business Combination, Integration Related Costs 22.6 [2] 0.0 43.1 [2] 0.0
Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal (0.5) 0.0 (6.7) 0.0
Specialty Brands        
Net sales 264.3 274.5 471.6 531.8
Restructuring and related charges, net 0.2 (0.2) 2.2 (10.4)
Depreciation and amortization 12.2 21.5 24.3 43.9
Specialty Generics        
Net sales 220.8 239.8 433.4 450.3
Depreciation and amortization 9.8 10.5 19.6 22.7
Corporate, Non-Segment        
Cost of sales [3] 4.5 5.3 7.6 7.3
Selling, general and administrative expenses [3] 59.9 42.0 121.5 100.4
Research and development expenses [3] 9.7 10.8 17.7 19.4
Operating Segments        
Operating Income (Loss) 131.9 95.8 241.5 153.8
Restructuring charges, net 0.2 (0.2) 2.2 (10.4)
Cost of sales 248.8 314.0 462.7 615.8
Selling, general and administrative expenses 90.7 85.9 176.6 164.4
Research and development expenses 13.9 18.4 26.4 37.7
Operating Segments | Specialty Brands        
Net sales 264.3 274.5 471.6 531.8
Operating Income (Loss) 87.4 44.0 138.0 76.1
Restructuring charges, net 0.2 (0.2) 2.2 (10.4)
Cost of sales 109.4 151.9 201.8 294.4
Selling, general and administrative expenses 59.4 66.3 118.4 125.4
Research and development expenses 8.3 12.1 15.6 25.5
Operating Segments | Specialty Generics        
Net sales 220.8 239.8 433.4 450.3
Operating Income (Loss) 44.5 51.8 103.5 77.7
Restructuring charges, net 0.0 0.0 0.0 0.0
Cost of sales 139.4 162.1 260.9 321.4
Selling, general and administrative expenses 31.3 19.6 58.2 39.0
Research and development expenses $ 5.6 $ 6.3 $ 10.8 $ 12.2
[1] Represents costs primarily related to the Separation during the three and six months ended June 27, 2025 and professional fees incurred as the Company explored potential sales of non-core assets to enable further deleveraging post-emergence from the 2023 Bankruptcy Proceedings during the three and six months ended June 28, 2024.
[2] Represents legal, financial, and other advisory and consulting expenses, which primarily relate to shareholder matters, integration planning, and regulatory costs associated with the Business Combination. Refer to Note 3 for further information on the Business Combination.
[3] Includes certain compensation, information technology, legal, environmental and other costs not charged to the Company’s reportable segments.